Zacks Investment Research
09 Sept 2026, 19:40 UTC · 6w ago
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
Impact · against what's priced in
Tandem Diabetes Care (TNDM) shows bullish long-term growth prospects and a strengthening revenue model, though these are balanced by competitive headwinds. The anticipated launch of the Mobi tubeless pump and the shift toward pharmacy-based reimbursement serve as primary catalysts for market share expansion.
- TNDM+0.40
No priced-in read yet
- In context
The shift to a pay-as-you-go pharmacy model (increasing to 10% of U.S. sales in Q2 2026) and the 510(k) submission for the Mobi tubeless pump provide tangible growth catalysts alongside a projected 35% long-term earnings growth rate.
Read from the article alone
